Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 10/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429410 | 1.00 | OPRK1 (0.58) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL29565390 | 1.00 | OPRK1 (0.58) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL4663398 | 1.00 | OPRK1 (0.58) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL29966565 | 1.00 | OPRK1 (0.58) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL4665471 | 0.92 | OPRK1 (0.61) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL147934 | 0.91 | OPRK1 (0.58) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL8617636 | 0.91 | OPRK1 (0.60) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL8615882 | 0.91 | OPRK1 (0.60) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL8613685 | 0.91 | OPRK1 (0.60) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL4663621 | 0.91 | OPRM1 (0.49) | OPRK1OPRD1SLC6A2SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20220362160-A1 | ABUSE RESISTANT CAPSULE | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-11-17 | — | — | US | claimed |
| US-11464747-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-10-11 | — | — | US | claimed |
| EP-3446681-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2020-12-23 | — | — | EP | claimed |
| US-10420729-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2019-09-24 | — | — | US | claimed |
| EP-2968129-B1 | ABUSE RESISTANT CAPSULE | SCHERER TECHNOLOGIES LLC R P (US) | 2018-09-05 | — | — | EP | claimed |
| US-20150056147-A1 | ABUSE-PROOFED DOSAGE FORM | Grünenthal GmbH (DE) | 2015-02-26 | — | — | US | claimed |
| US-20140271835-A1 | ABUSE RESISTANT CAPSULE | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2014-09-18 | — | — | US | claimed |
| EP-1558257-B1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | GRUENENTHAL GMBH (DE) | 2013-12-25 | — | — | EP | claimed |
| US-20130195935-A1 | ABUSE-PROOFED DOSAGE FORM | GRUNENTHAL GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| EP-1515702-B1 | ABUSE-PROTECTED ADMINISTRATION FORM | GRUENENTHAL GMBH (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1558221-B1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | GRUENENTHAL GMBH (DE) | 2007-06-06 | — | — | EP | claimed |
| US-20050214223-A1 | Abuse-safeguarded dosage form | GRUENENTHAL GMBH (DE) | 2005-09-29 | — | — | US | claimed |
| US-20050186139-A1 | Abuse-proofed dosage form | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | claimed |
| US-20050176790-A1 | Pharmaceutical salts | GRUNENTHAL GMBH (DE) | 2005-08-11 | — | — | US | claimed |
| US-20050152843-A1 | Abuse-proofed dosage form | GRUNENTHAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| JP-2004527491-A | — | — | 2004-09-09 | — | — | JP | claimed |
| EP-1390023-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2004-02-25 | — | — | EP | claimed |
| WO-2002067916-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | claimed |
| WO-2002067651-A2 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2002-09-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176790-A1 | Pharmaceutical salts | SLC5A1, SLC5A2, SLC35A1 | OPRK1 1625/4885OPRD1 2232/4885SLC6A2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.